Compare Stocks → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APOPNASDAQ:CYTXOTCMKTS:ECIANASDAQ:NVIVNASDAQ:SINT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPOPCellect Biotechnology$13.17+0.4%$11.51$6.64▼$35.52$12.87M1.87479,845 shs17,400 shsCYTXCytori Therapeutics$1.63-1.8%$0.20$0.20▼$0.75$36.12M1.96915,302 shs17,176 shsECIAEncision$0.44$0.54$0.25▼$0.75$5.22M0.3741 shsN/ANVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsSINTSintx Technologies$0.04$0.09$0.02▼$1.82$812K1.4721.89 million shs33.39 million shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPOPCellect Biotechnology0.00%0.00%0.00%0.00%0.00%CYTXCytori Therapeutics0.00%-6.32%-12.83%-26.91%+517.42%ECIAEncision+1.44%-37.14%-12.00%-4.35%+12.82%NVIVInVivo Therapeutics0.00%0.00%0.00%-50.67%-75.70%SINTSintx Technologies-9.09%+73.52%-58.92%-87.84%-97.90%Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPOPCellect BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ACYTXCytori TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AECIAEncisionN/AN/AN/AN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPOPCellect BiotechnologyN/AN/AN/AN/ACYTXCytori TherapeuticsN/AN/AN/AN/AECIAEncisionN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/ASINTSintx Technologies2.00HoldN/AN/ACurrent Analyst RatingsLatest CYTX, NVIV, ECIA, SINT, and APOP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/5/2024SINTSintx TechnologiesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPOPCellect BiotechnologyN/AN/AN/AN/A$4.77 per shareN/ACYTXCytori Therapeutics$3.67M9.84N/AN/A$0.35 per share4.66ECIAEncision$7.35M0.71N/AN/A$0.21 per share2.10NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ASINTSintx Technologies$2.63M0.31N/AN/A$1.65 per share0.02Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPOPCellect Biotechnology-$5.62MN/A0.00∞N/AN/AN/AN/AN/ACYTXCytori Therapeutics-$12.63MN/A0.00∞N/A-242.60%-272.70%-56.23%N/AECIAEncision-$320K-$0.04N/A∞N/A-6.51%-18.97%-10.50%6/20/2024 (Estimated)NVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ASINTSintx Technologies-$8.26M-$3.42N/A∞N/A-314.39%-67.12%-45.49%5/20/2024 (Estimated)Latest CYTX, NVIV, ECIA, SINT, and APOP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023SINTSintx TechnologiesN/A-$0.09-$0.09-$0.09N/A$0.90 million2/14/2024Q3 2024ECIAEncisionN/A-$0.02-$0.02-$0.02N/A$1.58 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPOPCellect BiotechnologyN/AN/AN/AN/AN/ACYTXCytori TherapeuticsN/AN/AN/AN/AN/AECIAEncisionN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPOPCellect BiotechnologyN/A3.013.01CYTXCytori Therapeutics0.390.460.30ECIAEncision0.112.551.08NVIVInVivo TherapeuticsN/A14.3014.30SINTSintx TechnologiesN/A1.901.60OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPOPCellect Biotechnology4.84%CYTXCytori Therapeutics2.62%ECIAEncision8.20%NVIVInVivo Therapeutics13.78%SINTSintx Technologies18.38%Insider OwnershipCompanyInsider OwnershipAPOPCellect BiotechnologyN/ACYTXCytori Therapeutics0.66%ECIAEncision40.87%NVIVInVivo Therapeutics2.45%SINTSintx Technologies0.79%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPOPCellect Biotechnology2,020977,000N/ANot OptionableCYTXCytori Therapeutics3722.16 millionN/ANot OptionableECIAEncision3111.86 million7.02 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableSINTSintx Technologies4122.68 million22.50 millionNot OptionableCYTX, NVIV, ECIA, SINT, and APOP HeadlinesSourceHeadlineWhy SINTX Technologies Stock Is Getting Hammeredmsn.com - April 3 at 2:48 PMSINTX Technologies Announces Pricing of $1.5 Million Public Offering of Common Stockglobenewswire.com - April 3 at 9:00 AMWhy SINTX Technologies Stock Hit A New All-Time Low Todaymsn.com - April 1 at 3:51 PMDDC Appoints Vice President to Drive Operational Excellenceitnewsonline.com - March 30 at 6:23 PMSINTX Technologies Announces Proposed Public Offering of Common Stockglobenewswire.com - March 29 at 4:00 PMSINT Stock Earnings: SINTX Technologies Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 28 at 7:02 AMSintx Technologies Prices Public Offering Of $1.3 Mln Of Sharesmarkets.businessinsider.com - March 25 at 1:22 PMWhy SINTX Technologies Stock Is Down 50%msn.com - March 25 at 1:22 PMWhy Is Sintx Technologies (SINT) Stock Down 31% Today?investorplace.com - March 25 at 9:05 AMSINTX Technologies Announces Pricing of $1.3 Million Public Offering of Common Stockglobenewswire.com - March 25 at 9:00 AMUS Stocks Edge Lower; FedEx Posts Upbeat Earningsmsn.com - March 23 at 3:15 AMWhy SINTX Technologies Is Trading Higher Todayaol.com - March 22 at 10:14 PMGold Moves Lower; Lululemon Shares Plummetmsn.com - March 22 at 5:14 PMDow Dips 200 Points; Nike Shares Fall After Q3 Resultsmarkets.businessinsider.com - March 22 at 5:14 PMSINTX Technologies Announces Intend To Offer And Sell Shares Of Common Stock; Stock Down 34%markets.businessinsider.com - March 22 at 5:14 PMWhy SINTX Technologies Stock Is Nosedivingmsn.com - March 22 at 5:14 PMSINTX Technologies Announces Proposed Public Offering of Common Stockglobenewswire.com - March 22 at 8:30 AMSintx Technologies (SINT) Price Target Increased by 42.86% to 10.20msn.com - February 24 at 2:14 PMTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)benzinga.com - February 23 at 7:50 AMSINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKETfinance.yahoo.com - February 21 at 3:58 PMSINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKETglobenewswire.com - February 21 at 9:00 AMSINTX Technologies: Other Eventscbonds.com - February 16 at 10:37 AMSINTX Technologies subsidiary enters R&D agreement with the U.S. Army DEVCOM ARL for ceramic additive manufacturingtctmagazine.com - February 7 at 10:57 AMSintx Technologies just downgraded at Maxim, here's whyrealmoney.thestreet.com - February 5 at 5:59 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentApril 3, 2024 9:10 AMView Akebia Therapeutics Surges on FDA Approval for Anemia TreatmentHow and When to Roll Your Options Positions? March 27, 2024 9:32 AMView How and When to Roll Your Options Positions? DexCom Stock Gains from GLP-1 Diabetic UsersApril 2, 2024 7:16 AMView DexCom Stock Gains from GLP-1 Diabetic UsersSilicon Motion Proves That AI in Motion Stays in MotionApril 16, 2024 11:42 AMView Silicon Motion Proves That AI in Motion Stays in MotionPriceSmart Could Be the Smartest Buy of the YearApril 11, 2024 7:35 AMView PriceSmart Could Be the Smartest Buy of the YearAll Headlines Company DescriptionsCellect BiotechnologyNASDAQ:APOPCellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.Cytori TherapeuticsNASDAQ:CYTXCytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.EncisionOTCMKTS:ECIAEncision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.InVivo TherapeuticsNASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.Sintx TechnologiesNASDAQ:SINTSintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.